Exhibition Invitation | IGC2025: The 10th International Conference on Research, Development, and Industrialization of Cells and Derivatives
Release Date:
2025-10-20 15:39
IGC 2025: The 10th International Conference on Cell and Derivative Research, Development, and Industrialization Will be October 30–31 In Langham Place, Guangzhou Grandly inaugurated. Leveraging the Greater Bay Area’s policy advantages, this conference features a main venue and four specialized sessions, bringing together Huaxi Lecheng, Xiangxue, Baiji, Dabo, China Resources, Guanhao, Keyi, North Science Sinovac, Laien, Tiankeya, Qianhui, Aierpu, Xidi, Ruizhen, Sipu, Ai Yi, Aixiuma Wait 60+ Experts from top research institutions, leaders of leading enterprises, and partners from investment firms will jointly explore In vivo immune cell therapy, MSC/iPSC stem cell therapy, exosome therapy, and anti-aging medical aesthetics and cutting-edge tracks.
Shanghai Hycells Biotechnology Co., Ltd. Will make an appearance Booth C11
We cordially invite industry colleagues to visit our booth for交流.
Jointly explore the latest scientific research findings to boost the thriving development of the cell industry!
Hycells Biology Company Introduction
Shanghai Hycells Biotechnology Co., Ltd. Founded in 2021, the company has spent many years cultivating expertise in cell and gene therapy as well as large-molecule drug development, positioning itself as an innovative biotechnology firm that offers end-to-end integrated solutions spanning R&D, manufacturing, sales, and service for primary-cell–based products. To date, Hycells has established nearly 1,000 square meters of state-of-the-art R&D laboratories and has officially obtained GB/T 19001-2016/ISO 9001:2015 quality management system certification. The company has also been recognized as a “Shanghai High-Tech Enterprise” and a “Shanghai Specialized, Sophisticated, Distinctive, and Innovative SME.” Hycells is committed to becoming a world-leading one-stop provider of primary cells, associated reagents, and related services. Leveraging the platform advantages of its existing portfolio of immune-cell–related products and services, the company has built a robust and diversified donor pool comprising healthy donors from both China and abroad, and has developed a comprehensive donor management and project management system. This enables Hycells to offer clients end-to-end compliance support, including regulatory interpretation, policy analysis, domestic-investor designation, and international collaboration approval, ensuring full regulatory adherence throughout the approval process. Guided by core values that place talent at the foundation, quality first, and innovation at the heart of everything it does, Hycells uses technological innovation as its starting point to set new industry standards for domestic innovation and product substitution, thereby providing a solid foundation for the advancement and global leadership of China’s innovative pharmaceutical sector.
Introduction to Hycells Biological Products and Technologies
- Sample Services -
Peripheral Blood
Mobilized Blood
Cord Blood
Primary cells of animal origin
Disease samples
- Cultured products (HiXpan
Related News
HiXpan® Cell Culture Additive: Answers to Key Questions (Part 2)
Hycell’s maximum production capacity per batch is 200–400 units of the 500 mL format, ensuring stable supply and meeting customers’ ongoing production needs.
HiXpan® Cell Culture Additive: Key Questions and Answers (Part 1)
The blood‑derived raw materials used in HiXpan® cell culture additives comply with all regulatory requirements throughout collection, ethical review, informed consent, and commercial authorization, and are supported by a fully traceable supply chain.
This paper focuses on how Hycells transforms biological variability into engineering‑level determinism through a scientifically informed blending strategy and stringent control at the collection end.
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how Hycells proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board